Literature DB >> 24227984

Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature.

Kailun Jiang1, Seymour Brownstein, Harmanjatinder S Sekhon, Scott A Laurie, Kay Lam, Steven Gilberg, William Britton.   

Abstract

Choroidal metastasis is the most common intraocular neoplasm and is associated with significant morbidity. In a small percentage of patients, ocular manifestation may be the initial presentation of a systemic malignancy and can be diagnostically difficult to distinguish from ocular primary malignancies. Herein, we present a case of a never-smoker whose ocular pathology was integral to the diagnosis and management of a lung adenocarcinoma harboring a rare oncogene. Through this case, we have explored important diagnostic and therapeutic considerations of pulmonary metastases to the choroid.

Entities:  

Keywords:  Adenocarcinoma; Choroidal metastasis; Crizotinib; EML4-ALK translocation; Non-small cell lung carcinoma; Targeted therapy

Year:  2013        PMID: 24227984      PMCID: PMC3770219          DOI: 10.1016/j.sjopt.2013.06.011

Source DB:  PubMed          Journal:  Saudi J Ophthalmol        ISSN: 1319-4534


  34 in total

1.  Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Authors:  Yi-Long Wu; Wen-Zhao Zhong; Long-Yun Li; Xiao-Tong Zhang; Li Zhang; Cai-Cun Zhou; Wei Liu; Bin Jiang; Xin-Lin Mu; Jia-Ying Lin; Qing Zhou; Chong-Rui Xu; Zhen Wang; Guo-Chun Zhang; Tony Mok
Journal:  J Thorac Oncol       Date:  2007-05       Impact factor: 15.609

Review 2.  Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature.

Authors:  Navneet Singh; Pandurang Kulkarni; Ashutosh N Aggarwal; Bhagwant Rai Mittal; Nalini Gupta; Digambar Behera; Amod Gupta
Journal:  Medicine (Baltimore)       Date:  2012-07       Impact factor: 1.889

3.  ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

Authors:  Sanjay Popat; David Gonzalez; Toon Min; John Swansbury; Melissa Dainton; James G Croud; Alexandra J Rice; Andrew G Nicholson
Journal:  Lung Cancer       Date:  2011-08-19       Impact factor: 5.705

Review 4.  The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors:  Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal:  Eur J Cancer       Date:  2010-04-24       Impact factor: 9.162

5.  Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing.

Authors:  Rica Zinsky; Servet Bölükbas; Holger Bartsch; Joachim Schirren; Annette Fisseler-Eckhoff
Journal:  Gastroenterol Res Pract       Date:  2010-12-21       Impact factor: 2.260

6.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

Authors:  Marie Brevet; Maria Arcila; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

7.  Slow-growing lung cancer in a fixed population sample. Radiologic assessments.

Authors:  N Hayabuchi; W J Russell; J Murakami
Journal:  Cancer       Date:  1983-09-15       Impact factor: 6.860

8.  Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.

Authors:  Daphne W Bell; Brian W Brannigan; Keitaro Matsuo; Dianne M Finkelstein; Raffaella Sordella; Jeff Settleman; Tetsuya Mitsudomi; Daniel A Haber
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

9.  Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Authors:  Antonio Marchetti; Michele Milella; Lara Felicioni; Federico Cappuzzo; Luciana Irtelli; Maela Del Grammastro; Mariagrazia Sciarrotta; Sara Malatesta; Carmen Nuzzo; Giovanna Finocchiaro; Bruno Perrucci; Donatella Carlone; Alain J Gelibter; Anna Ceribelli; Andrea Mezzetti; Stefano Iacobelli; Francesco Cognetti; Fiamma Buttitta
Journal:  Neoplasia       Date:  2009-10       Impact factor: 5.715

10.  Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity.

Authors:  Shailaja Akunuru; Joseph Palumbo; Qihui James Zhai; Yi Zheng
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

View more
  5 in total

1.  Development of a new choroidal metastasis in resistance to crizotinib therapy in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Authors:  Zhi-Hua Cui; Yan Zhang; Ling-Ling Liang; Zhao-Hui Li; Inna Abramova; Qian Hao
Journal:  Int J Ophthalmol       Date:  2017-02-18       Impact factor: 1.779

2.  A case of orbital metastasis as disease progression of anaplastic lymphoma kinase-positive lung cancer treated with crizotinib.

Authors:  Yoshihiko Sakata; Kodai Kawamura; Kazuya Ichikado; Masakazu Yoshioka
Journal:  Case Rep Oncol       Date:  2015-01-14

3.  Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer.

Authors:  Tomoko Funazo; Kyohei Morita; Naoya Ikegami; Chisato Konishi; Satoshi Nakao; Ryo Ariyasu; Masato Taki; Kazuhiko Nakagawa; Moon Hee Hwang; Chie Yoshimura; Toshiaki Wakayama; Yasuo Nishizaka
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

4.  Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report.

Authors:  Shilan Liu; Xiao Liu; Ting Wang; Chunhua Zeng; Baichen Ren; Xiaodan Yu; Min Xu; Wenjuan Li; Zhihui Qiao; Chuanyun You; Qinghui Yang; Mei Chen
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

5.  Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.

Authors:  Elisa Gozzi; Francesco Angelini; Luigi Rossi; Valentina Leoni; Patrizia Trenta; Giuseppe Cimino; Silverio Tomao
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.